Biocon: Enhancing Global Healthcare

Fact Sheet

About:

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog.

A Credible Biopharma Enterprise:

- **1200+** patent application filed globally*
- **984** Patents granted*
- **448** Trademark Registrations*
- **7** Biologics including **2** Novels and **5** Biosimilars taken from Lab to Market
- **12** Anchor Brands : Insugen®, BASALOG®, ALZUMAb™, BIOMAb EGFR®, Abraxane®, CANMAb™, ERYPRO™, BLISTO®, STATIX®, TACROGRAF™, Cytosorb™, Cimivir™
- **~120** countries where our products are available
- **25+** cGMP approvals from international regulatory agencies*
- Key regulatory approvals from US, EU, Japan, France, Brazil, Mexico, Turkey, GCC etc.

Vision

To enhance global healthcare through innovative and affordable biopharma products for patients, partners and healthcare systems across the globe.

Revenue
₹35,699 million

R&D Spending
₹4,270 million

Employees
8,000+

*As of 31 March 2016

Industry Leadership:

- India's first and only publicly listed biotech company.
- Developed and launched India's first Novel Biologic, BIOMAb-EGFR®, for head and neck cancer.
- Developed novel first-in-class anti-CD6 humanized monoclonal antibody, Itolizumab, which has been launched as ALZUMAb™ for the treatment of chronic plaque psoriasis in India.
- CANMAb™, launched in India in 2014, is the first follow-on biologic Trastuzumab to be approved anywhere in the world.
- Biocon's Insulin Glargine, a long-acting insulin analog, is the first biosimilar from India to be approved and launched in Japan.
- Biocon is the largest Asian insulins player and the fourth largest producer of insulins in the world.

Manufacturing Locations

Bangalore

Malaysia

Hyderabad

Visakhapatnam

- Biocon is the world's largest statins manufacturer; its drug substance is being used to produce 'one in every three' statin pills globally.
- Biocon is developing Insulin Tregopil, a novel 'first-in-class' oral prandial insulin
- Among the highest R&D spenders in India.
- Ranked among Top 20 Global Biotech Employers by prestigious US-based Science magazine.

Growth Verticals: Aligned with Shifting Paradigms

Novel Biologics & Biosimilars
(rh-insulin, Insulin Analogs, Monoclonal Antibodies & Recombinant Proteins)



Syngene
(Molecular Biology, Biologics, Synthetic Chemistry, Bioinformatics & Clinical Research)

For more information contact:

Seema Ahuja

VP & Global Head of Communications

T: +91-80-2808-2222

Email: seema.ahuja@biocon.com